Evidence map›Paper›PMID 34834200›Full record

ReviewPharmaceutics2021

Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview.

Sabrina Rahman Archie, Abdullah Al Shoyaib, Luca Cucullo

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sabrina Rahman ArchieDepartment of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
Abdullah Al ShoyaibDepartment of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
Luca CuculloDepartment of Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI 48309, USA.ORCID 0000-0002-2827-7162

Funding

Testing tobacco smoke toxicity at the blood-brain barrierR01DA029121 · NIDA · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI ABBRUSCATO, THOMAS J, CUCULLO, LUCA · 2011 to 2021
$3.6M
Repurposing Metformin to Offset Stroke Risk and Injury in Comorbid Populations of SmokersR01NS117906 · NINDS · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI ABBRUSCATO, THOMAS J, CUCULLO, LUCA · 2020 to 2024
$2.9M
Blood and Brain Based Biomarkers of Injury to Assess the Cerebrovascular Impact of Emerging Alternatives to Classic Cigarette ProductsR01DA049737 · NIDA · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI ABBRUSCATO, THOMAS J, CUCULLO, LUCA · 2019 to 2021
$1.4M
NIDA NIH HHS 1R01DA049737NIDA NIH HHS 2R01DA029121NINDS NIH HHS 1R01NS117906
6 · The paper itself

Abstract

The blood-brain barrier (BBB) is a fundamental component of the central nervous system (CNS). Its functional and structural integrity is vital to maintain the homeostasis of the brain microenvironment by controlling the passage of substances and regulating the trafficking of immune cells between the blood and the brain. The BBB is primarily composed of highly specialized microvascular endothelial cells. These cells' special features and physiological properties are acquired and maintained through the concerted effort of hemodynamic and cellular cues from the surrounding environment. This complex multicellular system, comprising endothelial cells, astrocytes, pericytes, and neurons, is known as the neurovascular unit (NVU). The BBB strictly controls the transport of nutrients and metabolites into brain parenchyma through a tightly regulated transport system while limiting the access of potentially harmful substances via efflux transcytosis and metabolic mechanisms. Not surprisingly, a disruption of the BBB has been associated with the onset and/or progression of major neurological disorders. Although the association between disease and BBB disruption is clear, its nature is not always evident, specifically with regard to whether an impaired BBB function results from the pathological condition or whether the BBB damage is the primary pathogenic factor prodromal to the onset of the disease. In either case, repairing the barrier could be a viable option for treating and/or reducing the effects of CNS disorders. In this review, we describe the fundamental structure and function of the BBB in both healthy and altered/diseased conditions. Additionally, we provide an overview of the potential therapeutic targets that could be leveraged to restore the integrity of the BBB concomitant to the treatment of these brain disorders.

Indexed as

biological barriersdysfunctionendothelialstroketherapeutic targetstight junctionsviability

Identifiers

PMID34834200
PMCPMC8622070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.